"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial looking at pertuzumab for prostate cancer (BO17004)
This trial looked at pertuzumab (also called Omnitarg) for prostate cancer that was no longer responding to hormone therapy.
Doctors often use hormone therapy to treat prostate cancer. But usually at some point, prostate cancer becomes
Pertuzumab is a monoclonal antibody. Monoclonal antibodies are a type of biological therapy. They look for specific proteins on the surface of cells. Pertuzumab looks for a protein called HER2, which is made by some prostate cancers.
Doctors hoped that pertuzumab would be useful for treating hormone refractory prostate cancer. The aims of this trial were to
- See how well pertuzumab worked
- Find the best dose to give
- Learn more about the side effects
Summary of results
The trial team found that pertuzumab did not help men with hormone refractory prostate cancer.
The doctors measured the level of
The trial recruited 68 men. They all had pertuzumab every 3 weeks for up to 24 weeks. The researchers looked at 2 different doses.
- The level of PSA did not go down in any of the men
- In 22 men, the PSA level stayed the same
- In 45 men, the PSA level went up or scans showed that the cancer had got bigger
- The trial team did not have results for one man
Side effects included diarrhoea, fatigue and nausea. There were more serious side effects in 5 men, including changes to the heart.
As none of the men taking part had a drop in their PSA level, the trial was stopped.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof M Mason
Dr J Graham
Prof J de Bono